Klotho Neurosciences Company Leadership
| KLTO Stock | 0.34 0.01 3.03% |
Klotho Neurosciences employs about 3 people. The company is managed by 5 executives with a total tenure of roughly 7 years, averaging almost 1.0 years of service per executive, having 0.6 employees per reported executive. Analysis of Klotho Neurosciences' management performance can provide insight into the firm performance.
Klotho Neurosciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.7163) % which means that it has lost $0.7163 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.9828) %, meaning that it created substantial loss on money invested by shareholders. Klotho Neurosciences' management efficiency ratios could be used to measure how well Klotho Neurosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of the 12th of January 2026, Return On Tangible Assets is likely to drop to -47.06. In addition to that, Return On Capital Employed is likely to grow to -5. As of the 12th of January 2026, Total Current Assets is likely to grow to about 181.3 K, while Total Assets are likely to drop about 2 M.As of the 12th of January 2026, Common Stock Shares Outstanding is likely to drop to about 16.5 MKlotho Neurosciences maintains a total of 72.54 Million outstanding shares. Klotho Neurosciences holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as Klotho Neurosciences in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Klotho Neurosciences, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Klotho Neurosciences Workforce Comparison
Klotho Neurosciences is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 121. Klotho Neurosciences holds roughly 3.0 in number of employees claiming about 2.48% of equities under Health Care industry.
Klotho Neurosciences Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Klotho Neurosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Klotho Neurosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Klotho Neurosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
El-dada Riad Hussein over a month ago Acquisition by El-dada Riad Hussein of 20000 shares of Klotho Neurosciences, at 0.41 subject to Rule 16b-3 | ||
Zentman Samuel M over three months ago Acquisition by Zentman Samuel M of 10000 shares of Klotho Neurosciences, at 0.41 subject to Rule 16b-3 | ||
Leblanc Jeff over three months ago Acquisition by Leblanc Jeff of 156199 shares of Klotho Neurosciences, subject to Rule 16b-3 |
Klotho Neurosciences Notable Stakeholders
A Klotho Neurosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Klotho Neurosciences often face trade-offs trying to please all of them. Klotho Neurosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Klotho Neurosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Joseph PharmD | CEO, Founder | Profile | |
| Shalom MD | Medical Director | Profile | |
| Miguel Rodriguez | Chief Consultant | Profile | |
| Peter Moriarty | Chief Officer | Profile | |
| Jeffrey LeBlanc | Chief Officer | Profile |
About Klotho Neurosciences Management Performance
The success or failure of an entity such as Klotho Neurosciences often depends on how effective the management is. Klotho Neurosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Klotho management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Klotho management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (44.82) | (47.06) | |
| Return On Capital Employed | (5.27) | (5.00) | |
| Return On Assets | (2.88) | (2.73) | |
| Return On Equity | (5.97) | (5.67) |
Klotho Neurosciences Workforce Analysis
Traditionally, organizations such as Klotho Neurosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Klotho Neurosciences within its industry.Klotho Neurosciences Manpower Efficiency
Return on Klotho Neurosciences Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 2.1M | |
| Net Loss Per Executive | 1.2M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Klotho Neurosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Klotho Stock, please use our How to Invest in Klotho Neurosciences guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Klotho Neurosciences. If investors know Klotho will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Klotho Neurosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Klotho Neurosciences is measured differently than its book value, which is the value of Klotho that is recorded on the company's balance sheet. Investors also form their own opinion of Klotho Neurosciences' value that differs from its market value or its book value, called intrinsic value, which is Klotho Neurosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Klotho Neurosciences' market value can be influenced by many factors that don't directly affect Klotho Neurosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Klotho Neurosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Klotho Neurosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Klotho Neurosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.